Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

T-DM1

A drug used to treat certain patients with HER2-positive breast cancer that has already been treated with trastuzumab and a type of anticancer drug called a taxane. It is also being studied in the treatment of other types of cancer. T-DM1 contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some breast cancer cells. It also contains an anticancer drug called DM1, which may help kill cancer cells. T-DM1 is a type of antibody-drug conjugate. Also called ado-trastuzumab emtansine and Kadcyla.
More Information
Search NCI's Dictionary of Cancer Terms